GenOway Accelerates Its Global Expansion with New Japan Subsidiary

GenOway, a pioneering company in predictive preclinical solutions aimed at enhancing drug discovery, has recently announced the establishment of its wholly-owned subsidiary, GenOway Japan. This move is part of the company’s strategy to strengthen its presence in one of the largest preclinical research markets globally, ranking third after the United States and China.

Since its inception in 1999, GenOway has specialized in creating humanized preclinical models, offering valuable support to pharmaceutical researchers in selecting the most effective and safest drug candidates. With a client roster that includes major pharmaceutical firms like Takeda Pharmaceutical Company and Eisai, the establishment of GenOway Japan is seen as a significant step to tap into the rich market potential of the region. The technology developed by GenOway has played a pivotal role in the creation of groundbreaking therapies such as Opdivo, based on research by Nobel Laureate Tasuku Honjo.

The Japanese government views innovation in biotechnology as a national priority, reflecting in substantial investments and proactive engagement from local biotech companies. With the setup of GenOway Japan, the company aims to contribute further to this important sector and to replicate the successful business model it has established in Europe and North America.

This new subsidiary will focus on close interactions with clients in Japan, providing the same scientific value added that has been well-received in Western markets. GenOway plans to build a fully autonomous team comprising five scientists within the next year. The leadership for this initiative will be provided by Dr. Hideki Hanaoka, an expert with over 20 years of experience in the life sciences industry, genomics, and cell technologies.

Dr. Hanaoka's appointment as CEO of GenOway Japan underscores the company’s commitment to leverage local expertise. The board of directors will be chaired by Philippe Faucher, an independent director with a notable track record in Japan's biopharmaceutical innovation ecosystem. His strategic insights and in-depth knowledge of the market are expected to greatly benefit the subsidiary.

Dr. Alexandre Fleschard, the CEO of GenOway, commented, “Expanding internationally, especially in Asia, is a key factor in our strategic plan 'Route50+DATA' to achieve sales of 50 million euros by 2028. We aim to establish leadership in Japan's innovative preclinical models and achieve sales between 5 to 10 million euros in this market as part of our initiative.”

Dr. Hanaoka expressed his enthusiasm about GenOway's capabilities in delivering advanced humanized models, particularly in fields like immuno-oncology and immune inflammation. He stated, “By linking world-class technology with the innovative needs of the Japanese research community, we will accelerate the drug discovery process.”

Philip Faucher, with over 35 years of experience in the international pharmaceutical industry and significant time spent in Japan and Korea, has served in senior leadership roles at Sanofi and GSK. His ongoing contributions, including consulting engagements and board memberships within Japan's innovation ecosystem, reflect his commitment to enhancing the sector.

GenOway’s commitment to research and development in advanced preclinical models, particularly those utilizing gene-edited mice and rat strains, is underlined by its strategic focus. The company continually enhances its portfolio, responding to the high demand for predictive preclinical solutions that support effective drug development.

GenOway operates in over 28 countries globally, serving more than 380 clients, including some of the most respected academic institutions and 170 life sciences companies. The establishment of GenOway Japan represents a significant milestone in its ongoing global strategy, as it aims to foster close collaboration with Japanese researchers and pharmaceutical firms, ultimately enhancing the outcomes of drug development initiatives.

For more information about GenOway and its innovative solutions, visit www.genoway.com.

GenOway is publicly traded on Euronext Paris under the code ALGEN (ISIN: FR0004053510).